|
rs893595382
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In addition to classic markers of tauopathy, significant neuroinflammation and extensive gliosis were detected in AAV1-Tau(P301L) mice.
|
26276810 |
2015 |
|
rs893595382
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The Stress c-Jun N-terminal Kinase Signaling Pathway Activation Correlates with Synaptic Pathology and Presents A Sex Bias in P301L Mouse Model of Tauopathy.
|
30315879 |
2018 |
|
rs886039227
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conjunction with long disease duration and aging, our findings suggest that the F52L DCTN1 mutation may evoke severe tauopathy and moderate α-synucleinopathy.
|
29499916 |
2018 |
|
rs866604606
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These findings indicate that the major sites of tau phosphorylation, and the expression of kinases involved in tau phosphorylation are active in P310L mutation as in AD and other tauopathies.
|
14757934 |
2003 |
|
rs780325052
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice.
|
31156179 |
2019 |
|
rs779612015
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Here, to address the role of p25/Cdk5 in tauopathy, we generated double-transgenic mice by crossing mice overexpressing mutant human tau (P301S) with Δ<i>p35KI</i> mice.
|
28912154 |
2017 |
|
rs776045205
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice.
|
31156179 |
2019 |
|
rs775645890
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Here, to address the role of p25/Cdk5 in tauopathy, we generated double-transgenic mice by crossing mice overexpressing mutant human tau (P301S) with Δ<i>p35KI</i> mice.
|
28912154 |
2017 |
|
rs769483065
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These observations in vitro and cell lines are recapitulated in primary neurons and in vivo, as genetic reduction in RanBP9 not only ameliorates tauopathy in Tau-P301S mice but also rescues the deficits in synaptic integrity and plasticity.
|
29016855 |
2017 |
|
rs768194029
|
|
|
0.010 |
GeneticVariation |
BEFREE |
S-nitrosylation of E3 ubiquitin-protein ligase RNF213 alters non-canonical Wnt/Ca+2 signaling in the P301S mouse model of tauopathy.
|
30696811 |
2019 |
|
rs763872192
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Neuroprotective effects of low fat-protein diet in the P301L mouse model of tauopathy.
|
28456717 |
2017 |
|
rs760073870
|
|
|
0.010 |
GeneticVariation |
BEFREE |
P301L tauopathy: confocal immunofluorescence study of perinuclear aggregation of the mutated protein.
|
12127682 |
2002 |
|
rs755135182
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In this study, we examined whether BFT confers neuroprotection against tau phosphorylation and the generation of neurofibrillary tangles (NFTs) in the P301S mouse model of tauopathy.
|
29860433 |
2018 |
|
rs755135182
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The present study examined the effects of MB in the P301S mouse model of tauopathy.
|
24556215 |
2014 |
|
rs752410089
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice.
|
31156179 |
2019 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
α-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice.
|
29126071 |
2018 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To explore this interaction in vivo, we crossed a well-characterized human P301S-tau transgenic mouse model of tauopathy with human G2019S-LRRK2 transgenic mice or LRRK2 knockout (KO) mice.
|
29088368 |
2018 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
S-nitrosylation of E3 ubiquitin-protein ligase RNF213 alters non-canonical Wnt/Ca+2 signaling in the P301S mouse model of tauopathy.
|
30696811 |
2019 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We further demonstrate that peripheral administration of the same antibodies in the more rapidly progressive P301S tauopathy model not only reduces Tau pathology quantitated by biochemical assays and immunohistochemistry, but also significantly delays the onset of motor function decline and weight loss.
|
21841002 |
2011 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice.
|
31156179 |
2019 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating.
|
21698260 |
2011 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, transgenic mice expressing mutant (for example, P301S) human tau in nerve cells show the essential features of tauopathies, including neurodegeneration and abundant filaments made of hyperphosphorylated tau protein.
|
19503072 |
2009 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Tau silencing by siRNA in the P301S mouse model of tauopathy.
|
25687501 |
2014 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The present study examined the effects of MB in the P301S mouse model of tauopathy.
|
24556215 |
2014 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mice transgenic for human P301S tau protein exhibit many characteristics of human tauopathies, including neurodegeneration, the formation of neuronal tau inclusions in the brain and the development of a pronounced motor phenotype by 5 months of age.
|
20004218 |
2010 |